Experts from the University of Birmingham are among leading liver disease researchers who are meeting online at the 2021 Virtual International Liver Congress this week to discuss developments on the impact of the COVID-19 pandemic on people living with liver disease.
Summoned by the European Association for the Study of the Liver (EASL), the congress will take place from June 23 to 26 and will see the presentation of more than 1,500 abstracts of research studies examining the impact of COVID-19 on people with liver disease.
Research presented by researchers around the world includes new data indicating that people with advanced liver disease are extremely vulnerable to the novel coronavirus, and the results of a study indicating that the Pfizer-BioNTech SARS-CoV vaccine- 2 confers low immunity. in people with advanced liver disease.
Other announcements include new information on the impact of the COVID-19 pandemic on the incidence of alcohol-related liver disease and death rates for people with non-alcoholic fatty liver disease (NAFLD) and encouraging data on tenofovir in the prevention of severe COVID-19 disease. in people living with chronic hepatitis B.
Philip Newsome, EASL Secretary General and Professor of Experimental Hepatology and Director of the Center for Liver Research at the University of Birmingham, said: “Since 1966, the International Liver Congress has helped answer questions from most urgent research in hepatology, and this year is no different.
“We are starting to understand more clearly how disproportionately COVID-19 has an impact on people living with liver-related illnesses and the studies presented at ILC 2021 advance our knowledge on several fronts, knowledge that can potentially help to inform policy responses to the current pandemic. before.”
Notes to Editors:
- For more information, contact Emma McKinney, Communications Manager, University of Birmingham, +44 7815607157. You can also contact the after-hours press office on +44 (0) 7789 921165.
- For more information on the Congress, contact Michael Kessler, EASL Media Relations, tel. +34 655 792 699
- The University of Birmingham is ranked among the top 100 institutions in the world and its work brings people from all over the world to Birmingham, including researchers and teachers and more than 6,500 international students from almost 150 countries.
- the International Liver Congress ™ is EASL’s flagship event, attracting scientific and medical experts from around the world to learn about the latest liver research and exchange clinical experiences. Specialists in attendance present, share, debate and conclude on the latest science and research in hepatology, working to improve the treatment and management of liver disease in clinical practice. This year the congress is taking place entirely digitally due to the global health situation.
- Since its founding in 1966, the European Association for the Study of the Liver – a nonprofit organization – has more than 4,500 members from around the world, including many leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European association with international influence and with impressive experience in promoting liver disease research, supporting wider education and promoting promotion of changes in European liver policy.